J. Arts

发表

Histone Deacetylase Inhibitors: From Chromatin Remodelling to Experimental Cancer Therapeutics

J. Arts, S. D. Schepper, K. V. Emelen, 2005 .

On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2.

P. Parren, L. Aarden, J. V. D. van de Winkel, 1992, The Journal of clinical investigation.

Histone Deacetylase Inhibitors: A Brief Overview Of Their Role And Medicinal Chemistry

J. Arts, K. V. Emelen, P. Angibaud, 2010 .

Estradiol formation by human osteoblasts via multiple pathways: Relation with osteoblast function

H. Pols, M. Coughtrie, J. V. van Leeuwen, 1999, Journal of cellular biochemistry.

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies

M. Janicot, M. Jung, D. Johnson, 2007, British Journal of Cancer.

Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics.

J. Arts, S. de Schepper, K. van Emelen, 2003, Current medicinal chemistry.

Involvement of retinoic acid receptor alpha in the stimulation of tissue-type plasminogen-activator gene expression in human endothelial cells.

T. Kooistra, M. Lansink, K. Toet, 1995, European journal of biochemistry.

On the role of c-Jun in the induction of PAI-1 gene expression by phorbol ester, serum, and IL-1alpha in HepG2 cells.

T. Kooistra, J. Grimbergen, K. Toet, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey.

T. Kooistra, H. Princen, J. Arts, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Role of c-Jun and proximal phorbol 12-myristate-13-acetate-(PMA)-responsive elements in the regulation of basal and PMA-stimulated plasminogen-activator inhibitor-1 gene expression in HepG2.

P. Bosma, T. Kooistra, H. Rahmsdorf, 1996, European journal of biochemistry.

Preclinical anti‐myeloma activity of the novel HDAC‐inhibitor JNJ‐26481585

H. Einsele, R. Bargou, M. Chatterjee, 2010, British journal of haematology.

Initial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

linical Development Novel Tryptamine Derivative JNJ-26854165 Induces-Type p 53-and E 2 F 1-Mediated Apoptosis in Ther te Myeloid and Lymphoid Leukemias

M. Andreeff, K. Kojima, J. Burks, 2010 .

Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.

M. Janicot, L. van Hijfte, H. De Winter, 2005, European journal of medicinal chemistry.

Regulation of endothelial cell t-PA synthesis and release.

T. Kooistra, J. Emeis, J. Arts, 1994, International journal of hematology.

A first-in-man phase I study of R306465, a histone deacetylase (HDAC) inhibitor exploring pharmacokinetics (PK) and pharmacodynamics (PD) utilizing an electrochemiluminescent immunoassay in patients (p) with advanced tumours

M. Janicot, W. Aherne, J. Bono, 2007 .

On the Interaction of IgG Subclasses with the Low Affinity FcyRlla ( CD 32 ) on Human Monocytes , Neutrophils , and Platelets Analysis of a Functional Polymorphism to Human IgG 2

Peter, L. Aarden, J., 2013 .

Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.

M. Janicot, M. Noppe, L. van Hijfte, 2010, Bioorganic & medicinal chemistry letters.

Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells.

H. Pols, J. Gustafsson, J. V. van Leeuwen, 1997, Endocrinology.

Differential Expression of Estrogen Receptors α and β mRNA During Differentiation of Human Osteoblast SV-HFO Cells.

H. Pols, J. Gustafsson, J. V. van Leeuwen, 1997, Endocrinology.

JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity

W. Talloen, I. Hickson, M. Janicot, 2009, Clinical Cancer Research.

Stimulation of tissue-type plasminogen activator gene expression by sodium butyrate and trichostatin A in human endothelial cells involves histone acetylation.

T. Kooistra, M. Lansink, J. Grimbergen, 1995, The Biochemical journal.

Cell-type specific DNA-protein interactions at the tissue-type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro.

I. Herr, T. Kooistra, P. Angel, 1997, Nucleic acids research.

Leveraging premalignant biology for immune-based cancer prevention

J. Mesirov, T. Ideker, T. Rebbeck, 2016, Proceedings of the National Academy of Sciences.

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

Les Coulton, Karin Vanderkerken, Els Van Valckenborgh, 2009, Cancer research.

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models

P. Croucher, K. Vanderkerken, E. Menu, 2009, Leukemia.

The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias

Jared K Burks, M. Andreeff, K. Kojima, 2010, Molecular Cancer Therapeutics.

A novel experimental approach for the selective isolation and characterization of human RNase MRP

G. Pruijn, J. Arts, Merel Derksen, 2022, RNA biology.

Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells

J. Vialard, M. Janicot, T. Grand-Perret, 2006, Oncogene.

HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry,Biology and Clinical Benefit

M. Janicot, J. Bono, P. Fong, 2007 .

Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2

P. Scheet, J. Guinney, E. Hawk, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin

M. Janicot, L. Andries, J. Arts, 2003, Journal of Pharmacology and Experimental Therapeutics.

Mdm2 facilitates the association of p53 with the proteasome

S. Grossman, C. Blattner, M. Kaur, 2010, Proceedings of the National Academy of Sciences.

Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor.

G. Garcia-Manero, Z. Fang, W. Stevenson, 2010, Leukemia research.

Studies on the mechanism of sodium butyrate-stimulated t-PA expression in cultured human endothelial cells. Effects of trichostain A and 2-deoxy-D-glucose

T. Kooistra, J. Arts, 1995 .

Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors

L. Bijnens, M. Janicot, J. Voeten, 2006, Molecular Cancer Therapeutics.

JNJ-26854165 - a novel hdm2 antagonist in clinical development showing broad-spectrum preclinical antitumor activity against solid malignancies

C. Blattner, M. Janicot, P. Verhasselt, 2008 .

Inhibition of the Human Double Minute (HDM)-2 E3 Ubiquitin Ligase Activates Different Programmed Cell Death (PCD) Pathways in Models of Non-Hodgkin Lymphoma (NHL) with Wild Type (wt) and Mutant (mut) p53

Richard J. Jones, R. Orlowski, J. Arts, 2008 .

A first-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cells in vitro and ex vivo

M. Page, R. Bargou, K. Bommert, 2008 .

Polymorphism and functioning of a low-affinity IgG Fc receptor, hFcγRII (CD32)

P. Capel, J. G. Winkel, J. Arts, 1992 .

Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin

M. Janicot, L. Andries, J. Arts, 2003, Journal of Pharmacology and Experimental Therapeutics.